Stock Report

All about this stock under one free report Last Updated: 30-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Relmada Therapeutics (RLMD) Key Ratios

Stock Card factsheet share-fund-plan-icon

$4.33

up-down-arrow $-0.19 (-4.20%)

As on 28-Aug-2026 16:00EDT

Market cap

info icon

$494 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -- -- -- -- --
Net Profit 32.22 -30.89 8.68 14.98 5.12
EPS 47.77 61.34 57.97 21.26 12.75
Book Value -- -- 7.67 -35.24 -27.87
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info ----------
Net Margin info ----------
Return on equity info -104.63---42.26-94.05-132.33
Return on Capital info -104.63-----94.05-132.33
Return on Assets info -90.85---49.01-82.08-111.57
Debt to Equity (x) info ----0.00----

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
-94.05
-132.33
-87.51
-90.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-42.26

Lower than Peers by 1.97

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
-42.26
-94.05
-132.33
-87.51
-90.07
Peer Median
-40.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-49.01

Lower than Peers by 18.17

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
-49.01
-82.08
-111.57
-78.89
-83.48
Peer Median
-30.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
-10,159.14
Peer Median
-89.88
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

EBIT Growth

--

--

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
19.04
37.09
-24.88
Peer Median
-0.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

8.68

Higher than Peers by 15.86

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
8.68
28.25
19.04
37.09
-24.88
Peer Median
-7.19
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

57.97

Higher than Peers by 43.54

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
57.97
0.68
0.19
0.37
0.21
Peer Median
14.43
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

282.52

Higher than Peers by 292.98

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
282.52
--
--
--
--
Peer Median
-10.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

29.52

Higher than Peers by 23.71

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
29.52
14.62
4.45
8.00
12.26
Peer Median
5.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

29.52

Higher than Peers by 23.82

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
29.52
--
--
--
11.94
Peer Median
5.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
-37.34
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
--
Peer Median
0.07
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
-5.74
-0.20
-1.26
-0.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.40

Lower than Peers by 2.95

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
2.40
3.81
0.44
1.46
0.75
Peer Median
5.35
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.54

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
0.54
-4.12
0.37
5.76
0.28
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

494

Higher than Peers by 346

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Relmada Therapeutics (RLMD)
494
--
--
--
--
Peer Median
147
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...